HexafluOride, a Contrast Agent for Placenta Echo-angiography

PHASE3CompletedINTERVENTIONAL
Enrollment

55

Participants

Timeline

Start Date

October 12, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2019

Conditions
Pregnancy
Interventions
DRUG

Contrast agent: SonoVue®.

SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.

Trial Locations (2)

54511

CHRU de NANCY, Nancy

57085

Chr Metz Thionville, Metz

All Listed Sponsors
lead

Centre Hospitalier Régional Metz-Thionville

OTHER

NCT02884297 - HexafluOride, a Contrast Agent for Placenta Echo-angiography | Biotech Hunter | Biotech Hunter